Foamix Pharmaceuticals to price public offering of ordinary stock

Bookrunners Barclays, Cowen and Guggenheim Securities assist with deal

By Devika Patel

Knoxville, Tenn., April 1 – Foamix Pharmaceuticals Ltd. will conduct a public sale of ordinary stock with a 30-day greenshoe, according to a Form F-1 filed Wednesday with the Securities and Exchange Commission.

Barclays, Cowen and Co. and Guggenheim Securities are the bookrunning managers, and Oppenheimer & Co. is the co-manager.

Proceeds will be used for clinical trials, studies and general corporate proceeds, including product development and promotion.

The clinical-stage specialty pharmaceutical company is based in Rehovot, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.